Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ridgeback Capital Owns 6% of Celldex

A 13G filing has disclosed that Ridgeback Capital, a healthcare focused hedge fund managed by Wayne Holman, has acquired a total of 3.8 million shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX). This gives it over 6% of the $410 million market cap pharmaceutical company’s total shares outstanding. Ridgeback had reported owning 2.9 million shares of the stock at the beginning of October (see more of Holman’s stock picks). Celldex is expected to be unprofitable next year as well as this year, but optimism concerning the products it has in development have pushed the stock up 140% in the last year.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)